Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab with ICE or DHAP in Relapsed/Refractory DLBCL
NCT00823719Phase 2Completed
- Sponsor
- GSK
- Start
- May 2009
- Primary completion
- Jul 2011
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of ofatumumab in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), sponsored by GSK. Started May 2009; status: completed.
02
Drugs
ofatumumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00823719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00823719.